My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    AIDS Res Ther. 2008 Jun 3;5:10.

    Pre-clinical development as microbicide of zinc tetra-ascorbo-camphorate, a novel terpenoid derivative: potent in vitro inhibitory activity against both R5- and X4-tropic HIV-1 strains without significant in vivo mucosal toxicity.

    Saïdi H, Jenabian MA, Gombert B, Charpentier C, Mannarini A, Bélec L.

    Laboratoire de Virologie, Hôpital Européen Georges Pompidou, and Université Paris Descartes (Paris V), Paris, France.

    BACKGROUND: Terpenoid derivatives originating from many plants species, are interesting compounds with numerous biological effects, such as anti-HIV-1 activity. The zinc tetra-ascorbo-camphorate complex (or "C14"), a new monoterpenoid derivative was evaluated in vitro for its anti-HIV-1 activity on both R5- and X4-HIV-1 infection of primary target cells (macrophages, dendritic cells and T cells) and on HIV-1 transfer from dendritic cells to T cells. RESULTS: The toxicity study was carried out in vitro and also with the New Zealand White rabbit vaginal irritation model. C14 was found to be no cytotoxic at high concentrations (CC50 > 10 muM) and showed to be a potential HIV-1 inhibitor of infection of all the primary cells tested (EC50 = 1 muM). No significant changes could be observed in cervicovaginal tissue of rabbit exposed during 10 consecutive days to formulations containing up to 20 muM of C14. CONCLUSION: Overall, these preclinical studies suggest that zinc tetra-ascorbo-camphorate derivative is suitable for further testing as a candidate microbicide to prevent male-to-female heterosexual acquisition of HIV-1.

    PMID: 18522743 [PubMed]

    PMCID: PMC2426711

    Supplemental Content

    Click here to read Click here to read
    Write to the Help Desk